
Oncology NEWS International
- Oncology NEWS International Vol 18 No 4
- Volume 18
- Issue 4
Pathwork tissue test passes muster in multi-center investigation
A multi-institutional group has validated a predefined 1,550-gene expression profile for identifying tumor tissue of origin. Malignancies found in unexpected locations, or with poorly differentiated morphologies, can pose a challenge for tissue of origin determination.
A multi-institutional group has validated a predefined 1,550-gene expression profile for identifying tumor tissue of origin. Malignancies found in unexpected locations, or with poorly differentiated morphologies, can pose a challenge for tissue of origin determination.
Current histologic and imaging techniques fail to yield definitive identification, according to lead author Federico A. Monzon, MD and colleagues.
The group evaluated 547 frozen specimens representing 15 tissues of origin with the Pathwork Tissue of Origin Test, in which microarray technology measures gene expression pattern.
According to the study results, the test had an overall sensitivity of 87.8% and overall specificity of 99.4%. Performance within the subgroup of metastatic tumors (n = 258) was found to be slightly lower than that of the poorly differentiated and undifferentiated primary tumor subgroup, 84.5% and 90.7%, respectively (J Clin Oncol online, March 30, 2009).
Articles in this issue
almost 17 years ago
Aureon launches prostate cancer predictoralmost 17 years ago
Ascenta Therapeutics cements treatment potential of AT-101almost 17 years ago
Hologic nabs approval for two new HPV testsalmost 17 years ago
Soy may protect against breast cancer in Asian womenalmost 17 years ago
P53 mutation linked to advanced CRC in African-Americansalmost 17 years ago
Increased mortality risk cannot be excludedalmost 17 years ago
Research restores yoga’s role in active therapyalmost 17 years ago
MRS may eliminate need for invasive brain biopsyalmost 17 years ago
Who's Newsalmost 17 years ago
David Alberts: Survival of the fittestNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































